Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
Showing 961–1,020 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
…ysis of long-term survival data from phase II and III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(1…
…n immune checkpoint inhibitor (ICI) combination of anti-PD1 and anti-CTLA4. Treatment efficacy was evaluated by monitoring tumor growth, a…
…E tumour samples from NSCLC patients treated with perioperative nivolumab plus chemotherapy in the NADIM trial ( NCT03081689). Bulk RNA-s…
…9 non-small cell and n=2 small cell, respectively) treated with Pembrolizumab, Nivolumab or Durvalumab, either alone or in conjunction with c…
…d by RNAseq. The metabolic profile of DCs following exposure to rPCSK9 was analyzed by the SCENITH assay. PCSK9-mediated effects on va…
…tion immunotherapy exposureConclusions Melanoma tumor cells and immune checkpoint inhibitors cooperatively reprogram the bone marrow niche, resulting in ear…
…s ATR inhibitor, M6620 (VX970, berzosertib), and TOP1 inhibitor topotecan, in patients with relapsed SCLCs, validated the induction of MH…
…e abolished in Rorc fl/fl Lyz2-Cre or PCSK9-null mice. Notably, SR2211 enhanced anti-PD-1 efficacy.Conclusions We identified a tumor- …
…8-loaded nanoparticles and anti-PD1 therapy, in the presence of tamoxifen to fate-map pro-inflammatory TAMs. TAMs were profiled by flow c…
…rd blood CD34+ cells), without the need of supplementation with human IL-15.Methods genO-BRGSF-HIS mice were engrafted with A549 cells and …
…low cytometry (CD45, CD3, CD4, CD8, CD69, CD25, IFNg, Perforin, Granzyme B) and CFSE-based proliferation assays.Results sbPCI enabled robu…